ClinConnect ClinConnect Logo
Search / Trial NCT05169762

Feminizing Treatment in Transgender Women and Non-binary Persons

Launched by ODENSE UNIVERSITY HOSPITAL · Dec 23, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Gender Affirming Hormone Treatment Estrogen Cardiovascular Risk

ClinConnect Summary

This clinical trial is studying the effects of hormone treatment on transgender women and non-binary individuals who were assigned male at birth and are seeking gender-affirming feminizing treatment. The study aims to understand how these hormones might affect heart health over time, with participants being followed for up to ten years.

To be eligible for the trial, participants must be assigned male at birth and qualify for feminizing hormone treatment. There are no exclusions, so anyone who meets these criteria can join. Throughout the study, participants will receive regular check-ups to monitor their health and any potential cardiovascular effects from the hormone therapy. This research is important as it will help us better understand the long-term safety of hormone treatments for transgender women and non-binary individuals.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • assigned male at birth and eligeble for gender affirming feminizing treatment
  • Exclusion Criteria:
  • none
  • -

About Odense University Hospital

Odense University Hospital is a leading academic medical center located in Denmark, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital is committed to enhancing patient outcomes and fostering collaboration among multidisciplinary teams. With a focus on translating scientific discoveries into practical applications, Odense University Hospital leverages its state-of-the-art facilities and expertise to conduct rigorous trials across various medical fields, ensuring adherence to the highest ethical and regulatory standards. Through these efforts, the hospital aims to contribute significantly to the global body of medical knowledge and improve the quality of care for patients both locally and internationally.

Locations

Odense, , Denmark

Patients applied

0 patients applied

Trial Officials

Dorte Glintborg

Principal Investigator

Odense University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials